General Electric (GE) shares jumped over 6% during premarket trading on Tuesday after the embattled manufacturing giant reported first-quarter revenue of $27.3 billion, down 2% year-over-year, but higher than analysts’ projection of $26.92 billion.
The top line was lifted by strong performance in the Aviation segment, which grew 12%. The power segment, meanwhile, saw its revenue plunge 22% during the quarter.
Fourth-quarter adjusted earnings of 14 cents per share surpassed analysts’ projection of 9 cents per share.
General Electric (NYSE: GE) stock has shown some recovery this year increasing 26%, compared to the 50% plunge it saw in 2018. The industrial giant has been working hard on a turnaround to retain its mojo by selling off non-core assets and trying to pare down its debt and improve cash flows.
GE Industrial Free Cash Flows, excluding one-time items, narrowed 31% to negative $1.2 billion.
CEO Larry Culp said, ““I am encouraged by the improvements we are making inside GE. This is one quarter in what will be a multi-year transformation, and 2019 remains a reset year for us.”
READ: SERVICES LIKELY TO DRIVE APPLE’S POST-EARNINGS STOCK MOVEMENT
Last month, the industrial giant provided 2019 outlook, which sees GE Industrial returning to positive free cash flow (FCF) only in 2020 and improving in 2021. The company also added that for the current fiscal adjusted free cash flow for GE Industrial to be between negative $2 billion to zero.
EU fine
Earlier this month, antitrust regulators in the EU slapped a $58 million fine on GE for providing misleading information to the regulator a couple of years ago when the company acquired LM Wind, a rotor blade manufacturer based in Denmark. This adds to the woes of the already beleaguered firm, which has been fighting multiple battles to restore confidence among shareholders.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Comments